UBS Group
RVMD icon

UBS Group’s Revolution Medicines RVMD Stock Holding History

UBS Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02B Buy
5,448,364
+1,061,573
+24% +$155M 0.13% 145
2026
Q1 		$427M Buy
4,386,791
+1,298,854
+42% +$131M 0.06% 308
2025
Q4 		$246M Buy
3,087,937
+1,998,972
+184% +$131M 0.04% 478
2025
Q3 		$50.9M Buy
1,088,965
+574,212
+112% +$22.5M 0.01% 1608
2025
Q2 		$18.9M Buy
514,753
+32,646
+7% +$1.25M ﹤0.01% 2414
2025
Q1 		$17M Buy
482,107
+182,324
+61% +$7.4M ﹤0.01% 2509
2024
Q4 		$13.1M Buy
299,783
+106,704
+55% +$5.38M ﹤0.01% 2774
2024
Q3 		$8.76M Sell
193,079
-24,684
-11% -$1.07M ﹤0.01% 2496
2024
Q2 		$8.45M Sell
217,763
-87,216
-29% -$3.26M ﹤0.01% 2364
2024
Q1 		$9.83M Sell
304,979
-1,579
-0.5% -$46.8K ﹤0.01% 2289
2023
Q4 		$8.79M Buy
306,558
+209,399
+216% +$5.03M ﹤0.01% 2210
2023
Q3 		$2.69M Sell
97,159
-39,295
-29% -$1.17M ﹤0.01% 3159
2023
Q2 		$3.65M Sell
136,454
-1,907
-1% -$46.8K ﹤0.01% 2892
2023
Q1 		$3M Sell
138,361
-29,282
-17% -$721K ﹤0.01% 3006
2022
Q4 		$3.99M Buy
167,643
+134,940
+413% +$2.87M ﹤0.01% 2715
2022
Q3 		$645K Sell
32,703
-8,329
-20% -$183K ﹤0.01% 4121
2022
Q2 		$800K Sell
41,032
-49,117
-54% -$956K ﹤0.01% 3906
2022
Q1 		$2.3M Sell
90,149
-24,271
-21% -$528K ﹤0.01% 3306
2021
Q4 		$2.88M Sell
114,420
-2,930
-2% -$82.6K ﹤0.01% 3402
2021
Q3 		$3.23M Buy
117,350
+116,252
+10,588% +$3.38M ﹤0.01% 3139
2021
Q2 		$35K Sell
1,098
-340
-24% -$11.9K ﹤0.01% 6775
2021
Q1 		$66K Buy
1,438
+235
+20% +$10.5K ﹤0.01% 6284
2020
Q4 		$48K Buy
+1,203
New +$47.6K ﹤0.01% 6227
2020
Q3 		– Sell
-4,892
Closed -$154K – 8351
2020
Q2 		$154K Sell
4,892
-3,479
-42% -$109K ﹤0.01% 4995
2020
Q1 		$183K Buy
+8,371
New +$232K ﹤0.01% 4789

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

UBS Group's RVMD Position: Q2 2026 in Review

UBS Group increased its Revolution Medicines (RVMD) stake by 24% in Q2 2026, buying an estimated $155M and bringing the position to 5,448,364 shares worth $1.02B. The position accounts for 0.13% of the portfolio, ranked #145.

UBS Group first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • UBS Group held 5,448,364 shares of Revolution Medicines worth $1.02B as of Q2 2026.
  • UBS Group bought 1,061,573 Revolution Medicines shares in Q2 2026, an estimated $155M.
  • Revolution Medicines made up 0.13% of UBS Group's portfolio in Q2 2026, its #145 holding.
  • UBS Group first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.